Villejuif, 12 March 2024

The Lancet
A clinical trial proves the efficacy of sunitinib in the treatment of rare neuroendocrine tumors

Led by Dr. Éric Baudin, head of Gustave Roussy’s endocrine tumors committee, the European trial FIRSTMAPP is the first-ever randomized clinical trial concerning phaeochromocytomas and paragangliomas, rare neuroendocrine tumors. The results, published in February 2024 in The Lancet, show the efficacy of sunitinib, a tyrosine kinase inhibitor.

Listening and dialogue

Concerned about the well-being of patients and the quality of care, Gustave Roussy provides its patients with areas for listening and dialogue organised around medical mediation.

Since 2017, Dr Bernard Escudier has held the position of medical mediator.

His role is to establish a dialogue with the patient or relatives by providing them with a listening ear, answers and solutions.

Patient information

• Living Better with Cancer
• The Meeting and Information Area (ERI)
• Patient rights
• Administrative procedures
• Online payment

Villejuif, le 4 mars 2024

Gosselies, Belgium and Paris, France, March 1st, 2024

27th February 2024

Dana-Farber and Gustave Roussy to hold third Transatlantic Exchange: Annual scientific conference dedicated to advancing Oncology research and practice

Day-long session to focus on liquid biopsy as an emerging approach in precision cancer medicine.

Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address: Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.